Lallemand Pharma and Merck continue ISMIGEN® marketing in Latin America

Spurred by the success of ISMIGEN® in Latin America, Lallemand Pharma and Merck are pleased to announce the launch in Dominican Republic of ISMIGEN®, an immuno-modulating drug developed and produced by Lallemand Pharma. ISMIGEN® is recommended in the prevention of acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree in adults and children.

The release as fetched from its publisher. lallemandpharma.com ↗